OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Total Debt

Last Annual Value

549.00K

3-Year CAGR

-5%

5-Year CAGR

-64%

10-Year CAGR

-40%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Total Debt

OKUR · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
549.00K
-6.6%N/AN/A 
5.19B
501.6%538.2%79.5%
2.33M
-50.3%-30.2%N/A
5.25M
-22.2%-18.3%N/A
11.62M
-5.0%-6.2%-1.1%
6.95M
-15.3%-19.6%N/A
1.57M
-9.4%38.4%N/A
28.60M
-5.4%-5.6%N/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47